These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27461747)

  • 1. Case of desmoplastic melanoma with lung metastasis maintaining complete response after cessation of nivolumab.
    Murayama A; Itoh M; Ito K; Tanito K; Ishida K; Nobeyama Y; Nakagawa H
    J Dermatol; 2017 Mar; 44(3):e17-e18. PubMed ID: 27461747
    [No Abstract]   [Full Text] [Related]  

  • 2. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report.
    Yamamura K; Otsuka A; Kaku Y; Seidel JA; Nomura M; Nagai H; Matsumoto S; Kabashima K
    J Dermatol; 2017 May; 44(5):547-548. PubMed ID: 27461159
    [No Abstract]   [Full Text] [Related]  

  • 3. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma.
    Safa H; Bhosale P; Weissferdt A; Oliva ICG
    Immunotherapy; 2020 Apr; 12(5):293-298. PubMed ID: 32295435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma.
    Kato J; Hida T; Kamiya T; Sato S; Takahashi H; Torigoe T; Uhara H
    JAMA Dermatol; 2018 May; 154(5):621-622. PubMed ID: 29590278
    [No Abstract]   [Full Text] [Related]  

  • 5. A rapid response to pembrolizumab in a patient with metastatic melanoma.
    Bayo Calero J; Aviñó Tarazona V
    Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report.
    Shibata T; Iwashita N; Takama H; Yanagishita T; Takeo T; Oshima Y; Watanabe D; Tsuzuki T
    J Dermatol; 2020 Jan; 47(1):e6-e7. PubMed ID: 31701575
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
    Ansorge C; Seufert J; Meiss F; von Bubnoff D
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy.
    Perez MC; Yu HM; Markowitz J
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30108120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of histopathologic analysis in the recognition of melanoma: a plea for a combined diagnostic approach of histopathologic and dermoscopic evaluation.
    Soyer HP; Massone C; Ferrara G; Argenziano G
    Arch Dermatol; 2005 Feb; 141(2):209-11. PubMed ID: 15724017
    [No Abstract]   [Full Text] [Related]  

  • 10. The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report.
    Røe OD; Wahl SG
    J Med Case Rep; 2017 Mar; 11(1):82. PubMed ID: 28343447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.
    Miyazawa H; Yanagi T; Yamaguchi Y; Imafuku K; Kitamura S; Hata H; Uehara J; Ichikawa N; Ohno Y; Yoshida T; Homma S; Kawamura H; Taketomi A; Shimizu H
    J Dermatol; 2017 Aug; 44(8):959-962. PubMed ID: 28295515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient.
    Tanaka A; Ikinaga K; Kiyohara E; Tanemura A; Wataya-Kaneda M; Fujimura R; Mizui M; Isaka Y; Katayama I
    J Dermatol; 2017 Jun; 44(6):727-728. PubMed ID: 27461931
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid complete remission of metastatic melanoma after first-line treatment with nivolumab plus tumor-infiltrating lymphocytes.
    Zhao L; Yang Y; Li W; Han L; Lin H; Gao Q
    Immunotherapy; 2018 Sep; 10(13):1133-1136. PubMed ID: 30236024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ipilimumab-induced hypophysitis].
    Schleder S; Schreml S; Heiss P
    Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
    [No Abstract]   [Full Text] [Related]  

  • 15. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.
    Matsumura N; Ohtsuka M; Kikuchi N; Yamamoto T
    Acta Derm Venereol; 2016 Feb; 96(2):259-60. PubMed ID: 26270860
    [No Abstract]   [Full Text] [Related]  

  • 16. Pleural Metastasis From Cutaneous Malignant Melanoma.
    Mytinger AK; Lim KG; Kern RM; Mullon JJ; Edell ES; Saeed AI
    J Bronchology Interv Pulmonol; 2018 Jan; 25(1):54-56. PubMed ID: 28195965
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
    Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
    JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
    [No Abstract]   [Full Text] [Related]  

  • 18. Reddish plaque on the arm of a 53-year-old woman. Diagnosis: Desmoplastic melanoma (DM).
    Pretel M; Irarrazaval I; Lera M; Bernad I; Idoate MA
    J Am Acad Dermatol; 2014 Oct; 71(4):e121-2. PubMed ID: 25219723
    [No Abstract]   [Full Text] [Related]  

  • 19. Dermoscopy and the negative pigment network.
    Connolly D; Silverstein DI
    J Am Acad Dermatol; 2014 Feb; 70(2):e29-30. PubMed ID: 24438973
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.